Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk

References

• Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41(6):1103-10
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72(2):211-16
   PubMed Web of Science ®Google Scholar
• Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34(3):585-92
   PubMed Web of Science ®Google Scholar
• Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosclerosis 2010;212(1):305-9
   PubMed Web of Science ®Google Scholar
• Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28(2-3):69-75
   PubMed Web of Science ®Google Scholar
• Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69(2):325-31
   PubMed Web of Science ®Google Scholar
• Maksymowych WP. Spondyloarthritis in 2012: advances in pathogenesis through animal models and imaging. Nat Rev Rheumatol 2013;9(2):72-4
   PubMed Web of Science ®Google Scholar
• Qaiyumi S, Hassan ZU, Toone E. Seronegativespondyloarthropathies in lone aortic insufficiency. Arch Intern Med 1985;145(5):822-4
   PubMedGoogle Scholar
• Bergfeldt L, Insulander P, Lindblom D, et al. HLA-B27: an important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities. Am J Med 1988;85(1):12-18
   PubMed Web of Science ®Google Scholar
• Bergfeldt L. HLA B27-associated rheumatic diseases with severe cardiac bradyarrhythmias. Clinical features and prevalence in 223 men with permanent pacemakers. Am J Med 1983;75(2):210-15
   PubMed Web of Science ®Google Scholar
• Bergfeldt L, Moller E. Complete heart block-another HLA B27 associated disease manifestation. Tissue Antigens 1983;21(5):385-90
   PubMedGoogle Scholar
• Brown MA. Non-major-histocompatibility-complex genetics of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20(3):611-21
   PubMed Web of Science ®Google Scholar
• Rahman P, Siannis F, Butt C, et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006;65(7):919-23
   PubMed Web of Science ®Google Scholar
• Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis. J Rheumatol 2006;33(8):1631-3
   PubMed Web of Science ®Google Scholar
• Smith JA, Marker-Hermann E, Colbert RA. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract Res Clin Rheumatol 2006;20(3):571-91
   PubMed Web of Science ®Google Scholar
• Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39(11):1329-37
   PubMed Web of Science ®Google Scholar
• Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007;74(3):304-5
   PubMed Web of Science ®Google Scholar
• Wang X, Lin Z, Wei Q, et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009;29(11):1343-7
   PubMed Web of Science ®Google Scholar
• Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007;34(11):2285-90
   PubMed Web of Science ®Google Scholar
• Melis L, Elewaut D. Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease? Arthritis Res Ther 2009;11(3):233
   PubMed Web of Science ®Google Scholar
• Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008;58(8):2307-17
   PubMed Web of Science ®Google Scholar
• Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999;26(4):966-70
   PubMed Web of Science ®Google Scholar
• Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26(4):980-4
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007;13(3):242-4
   PubMed Web of Science ®Google Scholar
• Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010;69(3):618-23
   PubMed Web of Science ®Google Scholar
• Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 1981;40(1):66-9
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112(21):3337-47
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685-95
   PubMed Web of Science ®Google Scholar
• Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999;100(21):2124-6
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ, Liuzzo G, et al. T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001;76(10):1011-20
   PubMed Web of Science ®Google Scholar
• Kao AH, Sabatine JM, Manzi S. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 2003;15(5):519-27
   PubMed Web of Science ®Google Scholar
• Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009;15(8):921-9
   PubMed Web of Science ®Google Scholar
• Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009;15(8):930-9
   PubMed Web of Science ®Google Scholar
• Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med 2012;90(2):175-86
   PubMed Web of Science ®Google Scholar
• Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11(2):98-107
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999;340(2):115-26
   PubMed Web of Science ®Google Scholar
• Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30(2):260-8
   PubMed Web of Science ®Google Scholar
• Holm PW, Slart RH, Zeebregts CJ, et al. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med 2009;41(4):257-64
   PubMed Web of Science ®Google Scholar
• Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(10):1623-9
   PubMed Web of Science ®Google Scholar
• Wanders A, Heijde D, Landewe R, et al. Nonsteroidalantiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52(6):1756-65
   PubMed Web of Science ®Google Scholar
• Lassus A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease. Curr Med Res Opin 1976;4(1):65-9
   PubMedGoogle Scholar
• Leatham PA, Bird HA, Wright V, Fowler PD. The run-in period in trial design: a comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy. Agents Actions 1982;12(1-2):221-4
   PubMedGoogle Scholar
• Hopkins R, Bird HA, Jones H, et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985;44(3):189-93
   PubMed Web of Science ®Google Scholar
• Clark DW, Coulter DM. Psoriasis associated with rofecoxib. Arch Dermatol 2003;139(9):1223
   PubMedGoogle Scholar
• Ben-Chetrit E, Rubinow A. Exacerbation of psoriasis by ibuprofen. Cutis 1986;38(1):45
   PubMed Web of Science ®Google Scholar
• Meyerhoff JO. Exacerbation of psoriasis with meclofenamate. N Engl J Med 1983;309(8):496
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001;19(1 Suppl 22):S17-20
   PubMed Web of Science ®Google Scholar
• Radner H, Ramiro S, Buchbinder R, et al. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Cochrane Database Syst Rev 2012;1:CD008951
   PubMed Web of Science ®Google Scholar
• Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006;8(5):R153
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-44
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-8
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3(4):395-405
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52(20):1628-36
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Brookhart AM, Symmons DP, et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009;68(3):367-72
   PubMed Web of Science ®Google Scholar
• Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013;2:CD004524
   Google Scholar
• Micha R, Imamura F, Wyler vonBallmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108(9):1362-70
   PubMed Web of Science ®Google Scholar
• Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33(7):1422-30
   PubMed Web of Science ®Google Scholar
• Lubrano E, Scarpa R. Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 2012;64(2):107-12
   PubMedGoogle Scholar
• Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39(12):2004-12
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42(11):2325-9
   PubMed Web of Science ®Google Scholar
• Kim JY, Cho HJ, Sir JJ, et al. Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia. Cardiovasc Res 2009;82(3):550-60
   PubMed Web of Science ®Google Scholar
• Tabit CE, Holbrook M, Shenouda SM, et al. Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. Vasc Med 2012;17(2):101-7
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50(6):1939-50
   PubMed Web of Science ®Google Scholar
• Feng H, Li XY, Zheng JR, et al. Inhibition of the nuclear factor-kappaB signaling pathway by leflunomide or triptolide also inhibits the anthralin-induced inflammatory response but does not affect keratinocyte growth inhibition. Biol Pharm Bull 2005;28(9):1597-602
   PubMed Web of Science ®Google Scholar
• Grisar J, Aringer M, Koller MD, et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004;63(12):1632-7
   PubMed Web of Science ®Google Scholar
• Spadaro A, Riccieri V, Sili-Scavalli A, et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13(5):589-93
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64(6):859-64
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28(10):2274-82
   PubMed Web of Science ®Google Scholar
• Zanotti I, Greco D, Lusardi G, et al. Cyclosporine a impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion. PLoS ONE 2013;8(8):e71572
   PubMed Web of Science ®Google Scholar
• Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37(1):161-6
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Notarsanto I, de Pinto GD, et al. Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 2010;5(6):495-500
   PubMed Web of Science ®Google Scholar
• van Eijk IC, Peters MJ, Serné EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009;68(3):362-6
   PubMed Web of Science ®Google Scholar
• Capkin E, Karkucak M, Kose MM, et al. Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis. Rheumatol Int 2012;32(2):431-4
   PubMed Web of Science ®Google Scholar
• Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008;47(8):1203-7
   PubMed Web of Science ®Google Scholar
• Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010;55(2):333-8
   PubMed Web of Science ®Google Scholar
• Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology 2013;52(1):204-9
   PubMed Web of Science ®Google Scholar
• Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology 2012;51(5):910-14
   PubMed Web of Science ®Google Scholar
• Pieringer H, Stuby U, Pohanka E, Biesenbach G. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin Rheumatol 2010;29(7):723-7
   PubMed Web of Science ®Google Scholar
• Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33(12):2440-6
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Filippatos TD, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33(5):921-3
   PubMed Web of Science ®Google Scholar
• Mathieu S, Dubost JJ, Tournadre A, et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010;77(1):50-2
   PubMed Web of Science ®Google Scholar
• van Eijk IC, de Vries MK, Levels JH, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009;60(5):1324-30
   PubMedGoogle Scholar
• Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010;29(7):763-70
   PubMed Web of Science ®Google Scholar
• Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010;37(7):1386-94
   PubMed Web of Science ®Google Scholar
• Lubrano E, Soriano E, FitzGerald O. Can traditional DMARDs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol 2013;31(Suppl 78):S54-8
   PubMedGoogle Scholar
• Spadaro A, Lubrano E. Beyond anti-TNF-alpha agents in psoriatic arthritis. Expert Rev Clin Immunol 2013;9(6):507-9
   PubMed Web of Science ®Google Scholar
• Castro KR, Aikawa NE, Saad CG, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol 2011;2011:352686
   PubMedGoogle Scholar
• Angel K, Provan SA, Hammer HB, et al. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 2011;25(4):511-17
   PubMed Web of Science ®Google Scholar
• Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res 2013;56(2-3):348-57
   PubMed Web of Science ®Google Scholar
• van Denderen JC, Peters MJ, van Halm VP, et al. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 2006;65(5):695-6
   PubMed Web of Science ®Google Scholar
• Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012;64(9):36-46
   Google Scholar